leisure time -WSS

leisure time

author：entertainment 2025-09-27 23:52:48 - browse：6

LONDON — An experimental blood cancer drug from MorphoSys hit its primary target in a pivotal trial, the company announced late Monday, but the drug faltered in addressing patient symptoms, causing the company’s stock to fall in early Tuesday trading.

In the Phase 3 trial, the German company was testing its drug candidate pelabresib combined with the drug Jakafi against a Jakafi-placebo duo in patients with newly diagnosed myelofibrosis, a type of rare blood cancer. Jakafi is a standard myelofibrosis treatment.

The drug combination succeeded on its primary endpoint, with 66% of patients seeing at least a 35% reduction in spleen volume after 24 weeks versus 35% on the placebo regimen — an improvement the company in a release called “statistically significant and clinically meaningful.” Myelofibrosis is a rare bone marrow cancer that causes low blood cell counts and enlarged spleens, so reducing spleen volume is commonly used as the primary efficacy goal in clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Biden administration opens offers in Medicare drug price negotiations

knowledge

WSS

FDA drug safety: Singulair case shows systemic surveillance flaws

The EPA's new lead rule: How one expert crunched the numbers

Mayo Clinic plans $5B tech

UnitedHealth’s Optum accused of antitrust violations in California

FDA investigates CAR

Quicker fix for pulse oximeters urged during FDA public meeting

leisure time

leisure time

Wikipedia

Dobbs anniversary: the lost opportunity of abortion as health care

ReNAgade cuts staff seven months after raising $300 million

After affirmative action ruling, medical educators look to 'holistic review'

Some dementia cases could be undiagnosed liver disease

Bright Health sells Medicare Advantage business to Molina

ARCH Venture Partners is raising $3 billion for a life sciences fund

Bright Health sells Medicare Advantage business to Molina

With clinical trial data readouts, here's how to spot spin

How to save PrEP access — and even expand it

What don’t we know about an Alzheimer’s drug side effect?

Wikipedia

Congressmen charge Covid hearing ‘could have been an email’

Medicare drug price negotiation’s day in court

SAMSHA loosens regulations on methadone treatment centers

Takeda, Janssen join wearable maker to measure scratching

Cigna, Humana reportedly in talks to merge

Even great ERs can’t make up for American health disparities

focus

entertainment

knowledge

knowledge